A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD

This study is looking at a new medicine called varoglutamstat to see if it helps people with early Alzheimer's disease (AD), which affects memory and thinking. Varoglutamstat is a pill taken twice a day, aiming to target a harmful part of a protein called amyloid beta. The study is in Phase 2A, a trial stage where safety and right dosing are tested. Participants will take either varoglutamstat or a placebo (a fake pill) for at least 24 weeks. Researchers will check changes in memory and brain activity using a test called EEG (electroencephalogram), which measures brain waves. If this phase goes well, it will move to Phase 2B to test even more people and see if it works long term. Eligible participants are between 50-89 years old, have mild memory problems due to AD, and meet other health criteria.

• This study lasts at least 24 weeks.
• Participants will be randomly assigned to take either the real medicine or a placebo.
• There are no costs for participation, and travel expenses may be covered.